aberzoy
23.07.2004, 21:22
Добрый день Коллеги!
Интересует Ваше (эндокринологов :) мнение по двум публикациям:
1. Оценка результативности терапии тиреоидными гормонами в высоких дозах пациенток с диффузной мастопатией, сочетанной с эутиреоидным зобом
О. Г. Горюшина, В. Ф.Семиглазов,Е. И. Красильникова
[Ссылки могут видеть только зарегистрированные и активированные пользователи]
....После обследования 97 женщинам было назначено лечение L-тироксином в максимально переносимых дозах от 75-175 мкг/сут (ср. доза 138+1 мкг/сут), курсом от 3 до 5 месяцев (в среднем 3,4+0,02 месяцев).
...
Высокая результативность и отсутствие побочных эффектов при терапии ДМП тиреоидными гормонами в максимально переносимых дозах позволяет рекомендовать более широкое использование данного способа лечения в практической деятельности врачей (патент RU № 2172635).
2. The Effect of Supraphysiologic Levels of Iodine on Patients with Cyclic Mastalgia
Jack H. Kessler, PhD
The Breast Journal Volume 10 Issue 4 Page 328 - July 2004
doi:10.1111/j.1075-122X.2004.21341.x
Abstract:
A randomized, double-blind, placebo-controlled, multicenter clinical trial was conducted with 111 otherwise healthy euthyroid women with a history of breast pain. Patients had to document moderate or severe breast pain by recording a score 5 on a visual analog scale (VAS) of pain for 6 days per cycle and had to present with fibrosis involving at least 25% of both breast surfaces. Subjects could not be effectively treated with more conservative measures such as local heat or nonprescription analgesics. There was not a statistically significant difference in the dropout rate for patients on placebo (11.8%), 1.5 mg/day (31.3%), 3.0 mg/day (18.4%), or 6.0 mg/day (25%) of molecular iodine for 6 months. Physicians assessed breast pain, tenderness, and nodularity each cycle; patients assessed breast pain and tenderness with the Lewin breast pain scale at 3-month intervals and with a VAS at each cycle. A statistically significant improvement (p < 0.01) associated with dose was observed in the Lewin overall pain scale for all treated groups compared to placebo. Reductions in all three physician assessments were observed in patients after 5 months of therapy in the 3.0 mg/day (7/28; 25%) and 6.0 mg/day (15/27; 18.5%) treatment groups, but not the 1.5 mg/day or placebo group. Patients recorded statistically significant decreases in pain by month 3 in the 3.0 and 6.0 mg/day treatment groups, but not the 1.5 mg/day or placebo group; more than 50% of the 6.0 mg/day treatment group recorded a clinically significant reduction in overall pain. All doses were associated with an acceptable safety profile. No dose-related increase in any adverse event was observed.
(Полный текст статьи имеется)
С уважением,
Александр Берзой.
Интересует Ваше (эндокринологов :) мнение по двум публикациям:
1. Оценка результативности терапии тиреоидными гормонами в высоких дозах пациенток с диффузной мастопатией, сочетанной с эутиреоидным зобом
О. Г. Горюшина, В. Ф.Семиглазов,Е. И. Красильникова
[Ссылки могут видеть только зарегистрированные и активированные пользователи]
....После обследования 97 женщинам было назначено лечение L-тироксином в максимально переносимых дозах от 75-175 мкг/сут (ср. доза 138+1 мкг/сут), курсом от 3 до 5 месяцев (в среднем 3,4+0,02 месяцев).
...
Высокая результативность и отсутствие побочных эффектов при терапии ДМП тиреоидными гормонами в максимально переносимых дозах позволяет рекомендовать более широкое использование данного способа лечения в практической деятельности врачей (патент RU № 2172635).
2. The Effect of Supraphysiologic Levels of Iodine on Patients with Cyclic Mastalgia
Jack H. Kessler, PhD
The Breast Journal Volume 10 Issue 4 Page 328 - July 2004
doi:10.1111/j.1075-122X.2004.21341.x
Abstract:
A randomized, double-blind, placebo-controlled, multicenter clinical trial was conducted with 111 otherwise healthy euthyroid women with a history of breast pain. Patients had to document moderate or severe breast pain by recording a score 5 on a visual analog scale (VAS) of pain for 6 days per cycle and had to present with fibrosis involving at least 25% of both breast surfaces. Subjects could not be effectively treated with more conservative measures such as local heat or nonprescription analgesics. There was not a statistically significant difference in the dropout rate for patients on placebo (11.8%), 1.5 mg/day (31.3%), 3.0 mg/day (18.4%), or 6.0 mg/day (25%) of molecular iodine for 6 months. Physicians assessed breast pain, tenderness, and nodularity each cycle; patients assessed breast pain and tenderness with the Lewin breast pain scale at 3-month intervals and with a VAS at each cycle. A statistically significant improvement (p < 0.01) associated with dose was observed in the Lewin overall pain scale for all treated groups compared to placebo. Reductions in all three physician assessments were observed in patients after 5 months of therapy in the 3.0 mg/day (7/28; 25%) and 6.0 mg/day (15/27; 18.5%) treatment groups, but not the 1.5 mg/day or placebo group. Patients recorded statistically significant decreases in pain by month 3 in the 3.0 and 6.0 mg/day treatment groups, but not the 1.5 mg/day or placebo group; more than 50% of the 6.0 mg/day treatment group recorded a clinically significant reduction in overall pain. All doses were associated with an acceptable safety profile. No dose-related increase in any adverse event was observed.
(Полный текст статьи имеется)
С уважением,
Александр Берзой.